- Report
- April 2023
- 160 Pages
Global
From €4370EUR$4,949USD£3,788GBP
- Report
- April 2023
- 147 Pages
Global
From €4370EUR$4,949USD£3,788GBP
- Report
- August 2024
- 150 Pages
Global
From €2463EUR$2,789USD£2,135GBP
- Report
- August 2023
- 96 Pages
Global
From €3500EUR$4,246USD£3,140GBP
Pertuzumab is a monoclonal antibody used in the treatment of breast cancer. It is used in combination with other drugs, such as trastuzumab and chemotherapy, to treat HER2-positive breast cancer. Pertuzumab works by blocking the HER2 receptor, which is found on the surface of some cancer cells. This prevents the cancer cells from receiving signals that promote their growth and survival. Pertuzumab is approved for use in combination with trastuzumab and chemotherapy for the treatment of HER2-positive metastatic breast cancer. It is also approved for use in combination with trastuzumab and docetaxel for the treatment of HER2-positive early-stage breast cancer.
Companies in the Pertuzumab market include Roche, Merck, Pfizer, and AstraZeneca. Show Less Read more